Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility

Myoinositol Therapy May Adjust The Metabolic Deregulation in Infertile Polycystic Ovarian Syndrome (PCOS) Women Through Modulation of The TyG Index-BMI: A Comparative Study Versus Metformin

The study aimed to assess how a 6-month insulin sensitizer therapy impacts insulin resistance, glucose tolerance, and hormonal levels in women with PCOS. Researchers evaluated 156 PCOS patients, measuring their BMI, HOMA-IR (for insulin resistance), TyG index, TyG index-BMI, and total testosterone. Participants were divided into two groups, receiving either metformin or a myoinositol/d-chiro-inositol combination for six months, after which all parameters were re-evaluated to determine the percentage of change.

Inclusion Criteria:

• Patients presenting manifestations suggestive of having PCOS;
• Patients were free of exclusion criteria.

Exclusion Criteria:

• Patients who were maintained on a diet regimen, or/and regular exercise;
• Patients who were on medical therapy of PCOS, antidiabetic or/and antihypertensive therapy;
• Patients who underwent laparoscopic drilling;
• Patients with dyslipidemia, hereditary lipoprotein disorders:
• Patients with chronic liver or kidney diseases.